NCT05718323RecruitingPhase 2
A Single-arm Phase II Trial of the Addition of Niraparib to Anti-PD-L1 Antibody Maintenance in Patients With SLFN11-positive, Extensive-disease Small Cell Lung Cancer.
ETOP IBCSG Partners Foundation33 sites in 5 countries44 target enrollmentStarted: December 20, 2023Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 44
- Locations
- 33
- Primary Endpoint
- Progression-free survival (PFS) rate at 3 months by investigator assessment (according to RECIST v1.1)
Study Overview
Brief Summary
RAISE is an international, multicentre, single-arm phase II trial. The trial treatment consists of the addition of niraparib, 200 mg orally once daily to anti-PD-L1 antibody maintenance. The primary objective of this trial is to assess the clinical efficacy of the addition of niraparib to anti-PD-L1 monoclonal antibody maintenance treatment in patients with SLFN11-positive ED-SCLC which has not progressed following standard first-line chemo-immunotherapy.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Inclusion criteria for SLFN11-expression testing
- •Written IC part 1: for SLFN11-screening must be signed and dated by the patient and the investigator prior to sending any tumour material to the central laboratory.
- •Histologically or cytologically confirmed ED-SCLC (stage IV according to the 8th TNM classification).
- •Availability of FFPE tumour tissue for screening.
- •Inclusion criteria for trial participation
- •Written IC part 2: for trial participation must be signed and dated by the patient and the investigator prior to any trial-related intervention.
- •High SLFN11-expression on FFPE tumour material:
- •SLFN11-expression is determined at the central screening laboratory in Basel. Overexpression is defined as detectable protein expression by IHC in ≥20% of tumour cells.
- •Patients must have received standard first-line chemo-immunotherapy, consisting of 4 cycles of platinum-etoposide chemotherapy in combination with an anti-PD-L1 antibody (atezolizumab or durvalumab). Patients who started the immunotherapy at chemotherapy cycle 2 are eligible.
- •ED-SCLC must not have progressed during or after standard chemo-immunotherapy (as per RECIST v1.1).
- •Patients must be candidates for ongoing maintenance treatment with immune-checkpoint inhibition.
- •Adequate haematological function:
- •Adequate renal function:
- •Adequate liver function:
- •ECOG PS 0-2
- •Age ≥18 years
- •Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test within 4 weeks before enrolment and within 3 days before treatment start.
Exclusion Criteria
- •Symptomatic brain metastases
- •Any clinically active cancer, other than SCLC Exception: malignancies with negligible risk of metastases or death (e.g. 5-year OS rate of >90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localised prostate cancer, ductal carcinoma in situ, or stage I uterine cancer. Hormonal therapy for non-metastatic prostate or ductal carcinoma in situ is allowed.
- •Consolidating thoracic radiotherapy. Palliative radiotherapy to the brain or to bones is allowed.
- •History of idiopathic pulmonary fibrosis, organising pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan.
- •Any lung disease requiring systemic steroids in doses of >10 mg prednisolone (or equivalent dose of other steroid).
- •Any serious concomitant systemic disorders (for example active infection, unstable cardiovascular disease) which in the opinion of the investigator would compromise the patient's ability to complete the trial or interfere with the evaluation of the efficacy and safety of the protocol treatment.
- •Inadequately controlled hypertension, defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure >95 mmHg.
- •The patient must be considered stable and hypertension medically controlled.
- •History of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML).
- •Prior Reversible Encephalopathy Syndrome (PRES)
- •Severe renal or hepatic impairment.
- •Any clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach and/or bowels.
- •Treated with live vaccine within 30 days before enrolment.
- •Hypersensitivity to niraparib or any of its excipients (e.g., tartrazine).
- •Women who are pregnant or in the period of lactation.
- •Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the trial and within the required timelines after last dose of niraparib treatment.
- •Judgment by the investigator that the patient is unlikely to comply with trial procedures, restrictions and requirements.
Arms & Interventions
Treatment Arm
Experimental
Intervention: Niraparib (Drug)
Outcomes
Primary Outcomes
Progression-free survival (PFS) rate at 3 months by investigator assessment (according to RECIST v1.1)
Time Frame: From date of enrolment until 3 months post-enrolment
Defined as the rate of patients without a PFS event at 3 months after enrolment
Secondary Outcomes
- Progression-free survival (PFS)(From the date of enrolment until last tumour assessment (approximately 25-30 months after the enrolment of the first patient))
- Disease control rate (DCR) by investigator assessment (according to RECIST v1.1)(approximately 25-30 months after the enrolment of the first patient)
- Overall survival (OS)(From the date of enrolment until death from any cause (approximately 25-30 months after the enrolment of the first patient))
- Adverse events according to CTCAE v5.0(From the date of enrolment until last patient last visit (approximately 25- 30 months after enrolment of the first patient))
Investigators
Study Sites (33)
Loading locations...
Similar Trials
Terminated
Phase 2
Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic CancerMetastatic Pancreatic CancerNCT05442749Centre Leon Berard2
Recruiting
Phase 1
A multicenter single-arm phase II interventional study to evaluate the activity and safety of the combination of Platinum-Pemetrexed based chemotherapy plus Lorlatinib in ALK positive Non-Small Cell Lung Cancer (NSCLC) with exclusively extracranial disease progression on LorlatinibALK positive Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code: 10029522Term: Non-small cell lung cancer stage IV Class: 100000004864CTIS2023-506714-43-00Centro Di Riferimento Oncologico Di Aviano45
Withdrawn
Phase 2
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCCHepatocellular Carcinoma (HCC)NCT02406508Delcath Systems Inc.
Active, not recruiting
Phase 1
A single arm, multicenter, phase II trial of RAD001 as monotherapy in the palliative treatment of patient with locally advanced or metastatic transitional cell carcinoma after failure of platinum-based chemotherapyPalliative patients with locally advanced or metastatic transitional cell carcinoma after failure of platinum-based chemotherapyEUCTR2008-004575-21-BECliniques Universitaires St Luc40
Active, not recruiting
Phase 1
A single arm, multicenter, phase II trial of RAD001 as monotherapy in the palliative treatment of patient with locally advanced or metastatic transitional cell carcinoma after failure of platinum-based chemotherapyEUCTR2008-004575-21-FRCliniques Universitaires St Luc40